Copyright © 2005, European Society of Cardiology
Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia–reperfusion injury in rat hearts
aLaboratory of Experimental Cardiology, Department of Clinical Sciences and Bioimaging, and Center of Excellence of Aging, G. d'Annunzio University, Chieti, Italy
bDepartment of Biomorphology, Biology Section, "G. d'Annunzio" University, Chieti, Italy
cDepartment of Internal Medicine (DiMI), University of Genoa, Genoa, Italy
dCNR Institute of Clinical Physiology, Pisa, Italy
* Corresponding author. Department of Clinical Sciences and Bioimaging, "G. d'Annunzio" University of Chieti, C/o Ospedale S. Camillo de Lellis, Via Forlanini, 50, 66100 Chieti, Italy. Tel.: +39 0871 41512 fax: +39 0871 402817. Email address: rdecater{at}unich.it
Objective: Due to reported modulatory effects of statins on nitric oxide synthase (NOS) expression, we tested the hypothesis of protective effects of in vivo chronic treatment with rosuvastatin, a novel 3-hydroxy-3-methyl-glutaryl coenzyme A-reductase inhibitor, on ischemia–reperfusion injury, and investigated mechanisms involved.
Methods: After 3 weeks of in vivo treatment with rosuvastatin (0.2–20 mg/kg/day) or placebo, excised hearts from Wistar rats were subjected to 15 min global ischemia and 22–180 min reperfusion. We evaluated creatine-phosphokinase and nitrite levels in the coronary effluent, heart weight changes, microvascular permeability (extravasation of fluoresceine-labeled albumin), ultrastructural alterations, and the expression of endothelial (e) and inducible (i) nitric oxide synthase (NOS) (by reverse-transcription polymerase chain reaction and Western blotting).
Results: Rosuvastatin 0.2 and 2 mg/kg/day significantly reduced myocardial damage and vascular hyperpermeability, concomitant with a reduction in endothelial and cardiomyocyte lesions. At 2 mg/kg/day, rosuvastatin significantly increased eNOS mRNA and protein compared with untreated hearts, and conversely decreased iNOS mRNA and protein, as well as nitrite production after ischemia–reperfusion. The addition of the NOS inhibitor N
-nitro-L-arginine methylester (L-NAME, 30 µmol/L) significantly reduced cardioprotection against ischemia–reperfusion.
Conclusions: Chronic treatment with rosuvastatin before ischemia reduces ischemia–reperfusion injury and prevents coronary endothelial cell and cardiomyocyte damage by NO-dependent mechanisms.
KEYWORDS Statins; Rosuvastatin; Nitric oxide; Cardiomyocytes; Cardioprotection; Ischemia–reperfusion injury
Time for primary review 22 days
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  O. Adam, H.-R. Neuberger, M. Bohm, and U. Laufs Prevention of Atrial Fibrillation With 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Circulation, September 16, 2008; 118(12): 1285 - 1293. [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Kostapanos, H. J. Milionis, and M. S. Elisaf An Overview of the Extra-Lipid Effects of Rosuvastatin Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2008; 13(3): 157 - 174. [Abstract] [PDF]
|
|
|
|
 |
|
 J. C. S. Tsui, D. M. Baker, S. G. Shaw, and M. R. Dashwood Alterations in Nitric Oxide Synthase Isoforms in Acute Lower Limb Ischemia and Reperfusion Angiology, November 1, 2007; 58(5): 586 - 592. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Yin, J. Zhu, Z. Wang, H. Huang, J. Qian, Z. Li, and H. Jing Simvastatin attenuates cardiac isograft ischemia-reperfusion injury by down-regulating CC chemokine receptor-2 expression J. Thorac. Cardiovasc. Surg., September 1, 2007; 134(3): 780 - 788. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. P. Taylor, M. E. Olsen, and J. W. Starnes Improved postischemic function following acute exercise is not mediated by nitric oxide synthase in the rat heart Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H601 - H607. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. U. Muller Increased eNOS expression as a compensatory mechanism reducing {beta}-adrenergic responsiveness? Cardiovasc Res, September 1, 2005; 67(4): 575 - 577. [Full Text] [PDF]
|
|
|
|
|
|
U. Laufs and M. Bohm Cardiac effects of statins-advancements and open questions Cardiovasc Res, June 1, 2005; 66(3): 427 - 429. [Full Text] [PDF]
|
|